Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 79 articles: HTML format

Single Articles

October 2025
1. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
   Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
   Br J Cancer. 2025;133:874-885.
   PubMed     Abstract available
   
   
   
2. THONG MSY, Doege D, Koch-Gallenkamp L, Bertram H, et al
   Fatigue in long-term cancer survivors: prevalence, associated factors, and mortality. A prospective population-based study.
   Br J Cancer. 2025;133:831-843.
   PubMed     Abstract available
   
   
   September 2025
3. CUZICK J, Dowsett M
   Oestradiol and breast cancer prevention: a 40 year history and contemporary perspective.
   Br J Cancer. 2025 Sep 19. doi: 10.1038/s41416-025-03115.
   PubMed     Abstract available
   
   
   
4. STEGGALL J, Rajeeve V, Al-Subaie N, Naeem A, et al
   Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer.
   Br J Cancer. 2025 Sep 13. doi: 10.1038/s41416-025-03174.
   PubMed     Abstract available
   
   
   
5. WOYTASH JA, Lefebvre AEYT, Zhang Z, Xu B, et al
   CDCP1/mitochondrial Src axis increases electron transport chain function to promote metastasis in triple-negative breast cancer.
   Br J Cancer. 2025 Sep 4. doi: 10.1038/s41416-025-03163.
   PubMed     Abstract available
   
   
   
6. WANG T, Zeleznik OA, McGee EE, Brantley KD, et al
   Prospective study of circulating metabolomic profiles and breast cancer incidence among predominantly premenopausal women.
   Br J Cancer. 2025 Sep 4. doi: 10.1038/s41416-025-03159.
   PubMed     Abstract available
   
   
   
7. DUSTIN D, Gu G, Beyer AR, Herzog SK, et al
   Correction: RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
   Br J Cancer. 2025 Sep 1. doi: 10.1038/s41416-025-03096.
   PubMed    
   
   
   August 2025
8. WU Y, Zhou L, Zhao J, Peng Y, et al
   Relation knowledge distillation 3D-ResNet-based deep learning for breast cancer molecular subtypes prediction on ultrasound videos: a multicenter study.
   Br J Cancer. 2025 Aug 26. doi: 10.1038/s41416-025-03146.
   PubMed     Abstract available
   
   
   
9. STOER NC, Vangen S, Singh D, Fortner RT, et al
   Correction: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
   Br J Cancer. 2025 Aug 20. doi: 10.1038/s41416-025-03038.
   PubMed    
   
   
   
10. JING Y, Wu Y, Hu Q, Wu W, et al
    Remodelling hypoxic TNBC microenvironment restores antitumor efficacy of Vgamma9Vdelta2 T cell therapy.
    Br J Cancer. 2025;133:365-380.
    PubMed     Abstract available
    
    
    July 2025
11. HARVIE M, Pegington M, Howell A, Lim Y, et al
    Randomised phase-2 screening trial of intermittent energy restriction plus resistance exercise versus resistance exercise alone during chemotherapy for advanced breast cancer.
    Br J Cancer. 2025 Jul 31. doi: 10.1038/s41416-025-03129.
    PubMed     Abstract available
    
    
    
12. SOLMUNDE E, Pedersen RN, Norgaard M, Mellemkjaer L, et al
    Association between low-dose aspirin use and breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up.
    Br J Cancer. 2025 Jul 22. doi: 10.1038/s41416-025-03112.
    PubMed     Abstract available
    
    
    
13. FICORELLA L, Yang X, Mavaddat N, Carver T, et al
    Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population.
    Br J Cancer. 2025 Jul 17. doi: 10.1038/s41416-025-03117.
    PubMed     Abstract available
    
    
    
14. ALLEN G, Heiland EG, Teleka S, Glimelius I, et al
    Association of change in physical activity with use of outpatient specialist care and hospitalisations among breast cancer survivors with type 2 diabetes in Sweden.
    Br J Cancer. 2025 Jul 4. doi: 10.1038/s41416-025-03099.
    PubMed     Abstract available
    
    
    
15. SHIEN T, Hara F, Aogi K, Yanagida Y, et al
    Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial.
    Br J Cancer. 2025 Jul 4. doi: 10.1038/s41416-025-03097.
    PubMed     Abstract available
    
    
    
16. FLAHERTY RL, Falcinelli M, Hesketh AR, Patel BA, et al
    Biomarkers of psychological stress are associated with increased susceptibility to the development of breast and prostate cancer in BRCA1/2 mutation carriers.
    Br J Cancer. 2025 Jul 2. doi: 10.1038/s41416-025-03085.
    PubMed     Abstract available
    
    
    June 2025
17. BARRAUD S, Vacher S, Schiffler C, Wong J, et al
    Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature.
    Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03083.
    PubMed     Abstract available
    
    
    
18. SCOTT OW, Tin Tin S, Cavadino A, Elwood JM, et al
    Statin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics.
    Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03070.
    PubMed     Abstract available
    
    
    May 2025
19. PIMENTEL-PARRA GA, Garcia-Vivar C, Escalada-Hernandez P, San Martin-Rodriguez L, et al
    Systematic review of clinical practice guidelines for long-term breast cancer survivorship: assessment of quality and evidence-based recommendations.
    Br J Cancer. 2025 May 17. doi: 10.1038/s41416-025-03059.
    PubMed     Abstract available
    
    
    
20. TYRAKIS PA, Kampjut D, Steele GF, Lindstrom HJG, et al
    Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kalpha potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.
    Br J Cancer. 2025 May 13. doi: 10.1038/s41416-025-03035.
    PubMed     Abstract available
    
    
    
21. KOTSOPOULOS J, Maxwell CA, Lubinski J, Huzarski T, et al
    Parity, breastfeeding, and the risk of early-onset breast cancer in women with a BRCA1 pathogenic variant.
    Br J Cancer. 2025 May 2. doi: 10.1038/s41416-025-03029.
    PubMed     Abstract available
    
    
    
22. ABUDULA M, Astuti Y, Raymant M, Sharma V, et al
    Macrophages suppress CD8 + T cell cytotoxic function in triple negative breast cancer via VISTA.
    Br J Cancer. 2025 May 2. doi: 10.1038/s41416-025-03013.
    PubMed     Abstract available
    
    
    April 2025
23. PU Y, Xu F, He A, Li R, et al
    Repurposing chlorpromazine for the treatment of triple-negative breast cancer growth and metastasis based on modulation of mitochondria-mediated apoptosis and autophagy/mitophagy.
    Br J Cancer. 2025 Apr 11. doi: 10.1038/s41416-025-02992.
    PubMed     Abstract available
    
    
    
24. PETERS J, van Leeuwen MM, Moriakov N, van Dijck JAAM, et al
    Development of radiomics-based models on mammograms with mass lesions to predict prognostically relevant characteristics of invasive breast cancer in a screening cohort.
    Br J Cancer. 2025 Apr 6. doi: 10.1038/s41416-025-02995.
    PubMed     Abstract available
    
    
    
25. BUIJS SM, Jongbloed EM, van Bergen LEM, Ramakers CRB, et al
    Pseudo acute kidney injury in patients receiving CDK4/6 inhibitors.
    Br J Cancer. 2025;132:525-532.
    PubMed     Abstract available
    
    
    March 2025
26. CAIAZZA F, McGowan PM, Mullooly M, Murray A, et al
    Correction: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.
    Br J Cancer. 2025 Mar 14. doi: 10.1038/s41416-025-02973.
    PubMed    
    
    
    
27. SKRIVER C, Cronin-Fenton D, Borgquist S, Hansen Viuff J, et al
    Statin use and risk of breast cancer among women with benign breast disease: a Danish nationwide cohort study.
    Br J Cancer. 2025 Mar 8. doi: 10.1038/s41416-025-02974.
    PubMed     Abstract available
    
    
    
28. STEINDL A, Zach C, Berchtold L, Grisold A, et al
    Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer.
    Br J Cancer. 2025 Mar 1. doi: 10.1038/s41416-025-02967.
    PubMed     Abstract available
    
    
    February 2025
29. ELLIOTT H, Allen AJ, Forester ND, Graziadio S, et al
    Women's perspectives of molecular breast imaging: a qualitative study.
    Br J Cancer. 2025;132:276-282.
    PubMed     Abstract available
    
    
    January 2025
30. VILLETTE CC, Dupuy N, Brightman FA, Zimmermann A, et al
    Semi-mechanistic efficacy model for PARP + ATR inhibitors-application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs.
    Br J Cancer. 2025 Jan 28. doi: 10.1038/s41416-024-02935.
    PubMed     Abstract available
    
    
    December 2024
31. WU X, Ling Y, Zhang S, Zhang B, et al
    Advancing radiomics from contrast-enhanced mammography in breast cancer.
    Br J Cancer. 2024 Dec 12. doi: 10.1038/s41416-024-02932.
    PubMed    
    
    
    
32. WANG Q, Yu Y, Wang C, Jiang Z, et al
    Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer.
    Br J Cancer. 2024 Dec 10. doi: 10.1038/s41416-024-02917.
    PubMed     Abstract available
    
    
    November 2024
33. WANG W, Wang X, Jiang Y, Guo Y, et al
    Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis.
    Br J Cancer. 2024 Nov 28. doi: 10.1038/s41416-024-02906.
    PubMed     Abstract available
    
    
    
34. LUIJENDIJK MJ, Buijs SM, Jager A, Koolen SLW, et al
    Effects of tamoxifen on cognitive function in patients with primary breast cancer.
    Br J Cancer. 2024 Nov 26. doi: 10.1038/s41416-024-02914.
    PubMed     Abstract available
    
    
    
35. GIRITHAR HN, Krishnamurthy S, Carroll L, Guller A, et al
    Breast cancer metastasis progression is associated with elevated activity of kynurenine monooxygenase and kynureninase.
    Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02889.
    PubMed     Abstract available
    
    
    
36. SUN Y, Huo D
    Understanding genetic architecture of breast cancer: how can proteome-wide association studies contribute?
    Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02905.
    PubMed    
    
    
    
37. TRAN TXM, Chang Y, Choi HR, Kwon R, et al
    Correction: Height and breast cancer risk in premenopausal Korean women aged under 40 years of age.
    Br J Cancer. 2024 Nov 11. doi: 10.1038/s41416-024-02886.
    PubMed    
    
    
    
38. KAUFMANN M, Vaysse PM, Savage A, Kooreman LFS, et al
    Testing of rapid evaporative mass spectrometry for histological tissue classification and molecular diagnostics in a multi-site study.
    Br J Cancer. 2024;131:1298-1308.
    PubMed     Abstract available
    
    
    
39. TORR B, Jones C, Kavanaugh G, Hamill M, et al
    BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial.
    Br J Cancer. 2024;131:1506-1515.
    PubMed     Abstract available
    
    
    
40. WANG S, Wang T, Guo S, Zhu S, et al
    Whole tumour- and subregion-based radiomics of contrast-enhanced mammography in differentiating HER2 expression status of invasive breast cancers: A double-centre pilot study.
    Br J Cancer. 2024;131:1613-1622.
    PubMed     Abstract available
    
    
    October 2024
41. ZHAO T, Xu S, Ping J, Jia G, et al
    A proteome-wide association study identifies putative causal proteins for breast cancer risk.
    Br J Cancer. 2024 Oct 28. doi: 10.1038/s41416-024-02879.
    PubMed     Abstract available
    
    
    
42. EGELAND EV, Seip K, Skourti E, Oy GF, et al
    The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy.
    Br J Cancer. 2024 Oct 10. doi: 10.1038/s41416-024-02875.
    PubMed     Abstract available
    
    
    
43. TRAN TXM, Chang Y, Choi HR, Kwon R, et al
    Height and breast cancer risk in premenopausal Korean women aged under 40 years of age.
    Br J Cancer. 2024 Oct 7. doi: 10.1038/s41416-024-02846.
    PubMed     Abstract available
    
    
    
44. SABLIN MP, Gestraud P, Jonas SF, Lamy C, et al
    Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors.
    Br J Cancer. 2024;131:1060-1067.
    PubMed     Abstract available
    
    
    
45. CHIGUCHI G, Cho H
    What kind of tumour rupture requires adjuvant therapy?
    Br J Cancer. 2024;131:1109-1110.
    PubMed    
    
    
    September 2024
46. CASTRO-ESPIN C, Cairat M, Navionis AS, Dahm CC, et al
    Prognostic role of pre-diagnostic circulating inflammatory biomarkers in breast cancer survival: evidence from the EPIC cohort study.
    Br J Cancer. 2024 Sep 28. doi: 10.1038/s41416-024-02858.
    PubMed     Abstract available
    
    
    
47. PRASAD D, Baldelli E, Blais EM, Davis J, et al
    Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort.
    Br J Cancer. 2024 Sep 25. doi: 10.1038/s41416-024-02852.
    PubMed     Abstract available
    
    
    
48. PHILLIPS JB, Park SS, Lin CH, Cho J, et al
    SON is an essential RNA splicing factor promoting ErbB2 and ErbB3 expression in breast cancer.
    Br J Cancer. 2024 Sep 23. doi: 10.1038/s41416-024-02853.
    PubMed     Abstract available
    
    
    
49. JAVED SR, Skolariki A, Zameer MZ, Lord SR, et al
    Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer.
    Br J Cancer. 2024 Sep 9. doi: 10.1038/s41416-024-02833.
    PubMed     Abstract available
    
    
    
50. O'LEARY RL, Duijm LEM, Boersma LJ, van der Sangen MJC, et al
    Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade.
    Br J Cancer. 2024;131:852-859.
    PubMed     Abstract available
    
    
    
51. KRISTELEIT R, Leary A, Oaknin A, Redondo A, et al
    PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
    Br J Cancer. 2024;131:820-831.
    PubMed     Abstract available
    
    
    
52. GRAFINGER OR, Hayward JJ, Meng Y, Geddes-McAlister J, et al
    Cancer cell extravasation requires (i)plectin-mediated delivery of MT1-MMP at invadopodia.
    Br J Cancer. 2024;131:931-943.
    PubMed     Abstract available
    
    
    August 2024
53. ARUN B, Couch FJ, Abraham J, Tung N, et al
    BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing.
    Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02827.
    PubMed     Abstract available
    
    
    
54. ZOU R, Loke SY, Tang YC, Too HP, et al
    Correction: Development and validation of a circulating microRNA panel for the early detection of breast cancer.
    Br J Cancer. 2024 Aug 27. doi: 10.1038/s41416-024-02800.
    PubMed    
    
    
    
55. JOHNSON N, Bentley J, Wang LZ, Newell DR, et al
    Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
    Br J Cancer. 2024 Aug 19. doi: 10.1038/s41416-024-02813.
    PubMed    
    
    
    
56. YUAN J, Xiao M, Zheng Q
    Comment on: "A nationwide study of breast reconstruction after mastectomy in patients with breast cancer receiving postmastectomy radiotherapy: comparison of complications according to radiotherapy fractionation and reconstruction procedures".
    Br J Cancer. 2024 Aug 1. doi: 10.1038/s41416-024-02807.
    PubMed    
    
    
    July 2024
57. LOHFELD L, Sharma M, Bennett D, Gavin A, et al
    Correction: Impact of the COVID-19 pandemic on breast cancer patient pathways and outcomes in the United Kingdom and the Republic of Ireland - a scoping review.
    Br J Cancer. 2024 Jul 25. doi: 10.1038/s41416-024-02791.
    PubMed    
    
    
    
58. BESSE A, Sedlarikova L, Buechler L, Kraus M, et al
    HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
    Br J Cancer. 2024 Jul 5. doi: 10.1038/s41416-024-02774.
    PubMed     Abstract available
    
    
    
59. YAGHJYAN L, Heng YJ, Baker GM, Murthy D, et al
    Associations of stem cell markers CD44, CD24 and ALDH1A1 with mammographic breast density in women with benign breast biopsies.
    Br J Cancer. 2024;131:325-333.
    PubMed     Abstract available
    
    
    June 2024
60. POSSENTI I, Scala M, Carreras G, Bagnardi V, et al
    Exposure to second-hand smoke and breast cancer risk in non-smoking women: a comprehensive systematic review and meta-analysis.
    Br J Cancer. 2024 Jun 28. doi: 10.1038/s41416-024-02732.
    PubMed     Abstract available
    
    
    
61. BOMAN C, Liu X, Eriksson Bergman L, Sun W, et al
    A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression.
    Br J Cancer. 2024 Jun 28. doi: 10.1038/s41416-024-02777.
    PubMed     Abstract available
    
    
    
62. ZHU T, Huang YH, Li W, Wu CG, et al
    A non-invasive artificial intelligence model for identifying axillary pathological complete response to neoadjuvant chemotherapy in breast cancer: a secondary analysis to multicenter clinical trial.
    Br J Cancer. 2024 Jun 25. doi: 10.1038/s41416-024-02726.
    PubMed     Abstract available
    
    
    
63. POUMEAUD F, Morisseau M, Cabel L, Goncalves A, et al
    Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.
    Br J Cancer. 2024 Jun 25. doi: 10.1038/s41416-024-02766.
    PubMed     Abstract available
    
    
    
64. ZUO W, Wang Z, Qian J, Ma X, et al
    QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controll
    Br J Cancer. 2024 Jun 21. doi: 10.1038/s41416-024-02751.
    PubMed     Abstract available
    
    
    
65. RYU H, Shin KH, Chang JH, Jang BS, et al
    A nationwide study of breast reconstruction after mastectomy in patients with breast cancer receiving postmastectomy radiotherapy: comparison of complications according to radiotherapy fractionation and reconstruction procedures.
    Br J Cancer. 2024 Jun 5. doi: 10.1038/s41416-024-02741.
    PubMed     Abstract available
    
    
    
66. TSOULAKI O, Tischkowitz M, Antoniou AC, Musgrave H, et al
    Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.
    Br J Cancer. 2024;130:2027-2036.
    PubMed     Abstract available
    
    
    May 2024
67. TREEKITKARNMONGKOL W, Shah V, Kai K, Katayama H, et al
    Epigenetic activation of SOX11 is associated with recurrence and progression of ductal carcinoma in situ to invasive breast cancer.
    Br J Cancer. 2024 May 17. doi: 10.1038/s41416-024-02697.
    PubMed     Abstract available
    
    
    
68. HAM B, Kim SY, Kim YA, Han D, et al
    Persistence and enrichment of dominant T cell clonotypes in expanded tumor-infiltrating lymphocytes of breast cancer.
    Br J Cancer. 2024 May 15. doi: 10.1038/s41416-024-02707.
    PubMed     Abstract available
    
    
    
69. STOER NC, Vangen S, Singh D, Fortner RT, et al
    Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
    Br J Cancer. 2024 May 13. doi: 10.1038/s41416-024-02590.
    PubMed     Abstract available
    
    
    
70. LOHFELD L, Sharma M, Bennett D, Gavin A, et al
    Impact of the COVID-19 pandemic on breast cancer patient pathways and outcomes in the United Kingdom and the Republic of Ireland - a scoping review.
    Br J Cancer. 2024 May 4. doi: 10.1038/s41416-024-02703.
    PubMed     Abstract available
    
    
    
71. SHEN F, Jiang G, Philips S, Cantor E, et al
    Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE.
    Br J Cancer. 2024;130:1348-1355.
    PubMed     Abstract available
    
    
    
72. NG CW, Tsang YTM, Gershenson DM, Wong KK, et al
    The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
    Br J Cancer. 2024;130:1875-1884.
    PubMed     Abstract available
    
    
    April 2024
73. HANNA D, Merrick S, Ghose A, Devlin MJ, et al
    Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom.
    Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02685.
    PubMed     Abstract available
    
    
    
74. CHANG CY, Jones BL, Hincapie-Castillo JM, Park H, et al
    Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors.
    Br J Cancer. 2024 Apr 18. doi: 10.1038/s41416-024-02680.
    PubMed     Abstract available
    
    
    
75. BRAUN M, Piasecka D, Sadej R, Romanska HM, et al
    FGFR4-driven plasticity in breast cancer progression and resistance to therapy.
    Br J Cancer. 2024 Apr 17. doi: 10.1038/s41416-024-02658.
    PubMed     Abstract available
    
    
    
76. ARSHAD M, Azad A, Chan PYK, Vigneswara V, et al
    Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models.
    Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02665.
    PubMed     Abstract available
    
    
    
77. ALEXANDER J, Schipper K, Nash S, Brough R, et al
    Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer.
    Br J Cancer. 2024 Apr 10. doi: 10.1038/s41416-024-02679.
    PubMed     Abstract available
    
    
    March 2024
78. LIU X, Cheng X, Xie F, Li K, et al
    Persistence of peripheral CD8 + CD28- T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer.
    Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02610.
    PubMed     Abstract available
    
    
    
79. TEN VELDE DE, Duijm LEM, van der Sangen MJC, Schipper RJ, et al
    Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme.
    Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02633.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.